Questions for January 1. a. WHY is Endo giving back the global rights?
b. Is it due to disappointing results?
c. or Is it they are unwillimg to go for 1st line uasage?
d. or they cannot come up with an acceptacble protocol to satisfy FDA requirement, ie. coming up with a comparator that trial patients would go for?
2. Who is continuing to pay for the Urocidin needed to finish the treatment for those patients that have been in the P3B?
3. a. What is the amount of royalty do we have to give to Endo?
b. How long?
c. Since Endo's target and work was on the refractory segment, are they only getting royalty from revenue in that segment?
4. How many patients did we have in the P3B?
5. What was the result in P3b???
6 a. Will the combined number of patients treated with Urocidin in the P3a and P3b satisfy the trial size requirement for Canada Health NOC/c approval criteria?
b. Is the portion of patients using Mtimycin C acceptable as comparator?
7. Do we need to do more trials to get the approval from Canada?
8. Where can we get the funds?
9. How long will it take?
10. If we need to get more partner to fund the studies, what can we offer them? Shall we end up giving the shop away since we are not in a position og strength at this point?
11. The white elephant in the house...any thought of selling off the Human Health?
You guys are free to add on...